TARGET AUDIENCE

Late-stage trainees or junior faculty in various disciplines of adult or pediatric neuro-oncology, including neurology, medical oncology, radiation oncology, neurosurgery, or allied health or scientific trainees involved in clinical trial design and conduct.

STATEMENT OF NEED/PROGRAM OVERVIEW

Effective neuro-oncology treatment that encompasses both primary benign and malignant CNS tumors and metastatic CNS tumors remains a largely unmet clinical need with poor prognosis for many patients despite aggressive treatment with standard modalities (surgery, radiation, chemotherapy). Increased availability of and participation in well-designed clinical trials in neuro-oncology is vital for establishing new, effective treatments for CNS tumor patients. This course will emphasize communication across multi-disciplinary teams and provide foundational didactic background knowledge and unique mentored clinical trial design opportunities. This will also allow for collaboration between new and emerging investigators leading neuro-oncology clinical trials and members of the clinical research team to expand the number and quality of clinical trials available to patients with CNS tumors.

EDUCATIONAL OBJECTIVES

After participating in this CME activity, participants should be able to:

• Describe best practice approaches to clinical trial design (phase 0, 1, 2, 3) in neuro-oncology.
• Summarize common options for inclusion/exclusion criteria as well as primary, secondary, and exploratory outcome measures in neuro-oncology clinical trials and their potential impact on enrollment.
• Explain common statistical designs for clinical trials in neuro-oncology.
• Outline the clinical trial pre-activation and post-activation tasks for efficient conduct and analysis of studies.

_{Physician Accreditation StatemenT}

The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

_{Instructions to Receive Credit, Claim Certificate of Participation}

In order to receive credit or claim your certificate of participation for this activity, the participant must attend the meeting in-person and complete the program evaluation. A CME/CE evaluation link will be emailed to each participant within the coming weeks after the conference conclusion from the Society for Neuro-Oncology with the subject line "Claim CME, or Certificate of Participation for the 2026 Clinical Trial Design and Protocol Development Workshop." Physicians should only claim CME credit commensurate with the time they spent in the activity.

For technical assistance with claiming CME credit, please email academy@soc-neuro-onc.org

Deadline to claim CE Credit is Friday January 8, 2027, at 11:59 pm ET.

_{Refund/Cancellation Policy}

The deadline for cancellations with refund is Friday, October 30, 2026. Cancellations must be received in writing, and a $50 cancellation fee will be assessed. Cancellations received after the deadline date cannot be refunded, but the meeting registration can be transferred to another person with written authorization.

Please note that your SNO membership must be current if you have chosen to register as a SNO member. SNO reserves the right to confirm that you have registered in the correct category. Payment must be received in full before access to the meeting can be granted. Email all cancellation and transfer requests to Program Registrar Caroline Noor, caroline@soc-neuro-onc.org.

_{Disclosure of Relevant Financial Relationships}

The Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology in accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO.

_{Disclosure of Unlabeled Use}

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

_Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

_{SNO CME Contact Information}

For more information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at melesa@soc-neuro-onc.org